Metoclopramide Orion (Metoclopramide Hydrochloride)

Metoclopramide Orion acts on the central chemoreceptor trigger zone and gastrointestinal motility to alleviate several conditions.

• Nausea and vomiting: reduces episodes of acute and chemotherapy‑induced nausea.
• Gastroparesis: improves gastric emptying and relieves associated symptoms.
• Gastroesophageal reflux disease (GERD): decreases reflux episodes by enhancing lower esophageal sphincter tone.
• Migraine‑associated nausea: alleviates nausea that accompanies migraine attacks.

• Metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone, diminishing the vomiting reflex, and simultaneously stimulates acetylcholine release in the gastrointestinal tract, which enhances smooth‑muscle contractility and accelerates gastric emptying.

Metoclopramide Orion may cause a range of adverse reactions.

Common Side Effects

• Drowsiness: mild sedation or fatigue.
• Restlessness: feeling of inner tension or agitation.
• Diarrhea: increased bowel movements.
• Dry mouth: reduced salivation.
• Headache: mild to moderate head pain.

Serious or Rare Side Effects

• Extrapyramidal symptoms: involuntary muscle movements or rigidity.
• Tardive dyskinesia: persistent, irreversible facial or tongue movements.
• Neuroleptic malignant syndrome: rare, life‑threatening reaction with fever and muscle rigidity.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.

Before prescribing Metoclopramide Orion, clinicians should consider several safety aspects.

• Contraindication: avoid in patients with known hypersensitivity to metoclopramide.
• Pregnancy: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Breastfeeding: assess risk versus benefit because the drug is excreted in milk.
• Elderly patients: monitor closely for extrapyramidal reactions, especially in those with Parkinsonian disorders.
• Duration of therapy: limit use to the shortest effective period to reduce risk of tardive dyskinesia.
• Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Metoclopramide Orion can alter the activity of several co‑administered medicines.

Major Interactions (Avoid)

• Anticholinergic agents: may reduce the pro‑kinetic effect of metoclopramide.
• CNS depressants (e.g., opioids, benzodiazepines): increase risk of sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• CYP2D6 substrates (e.g., codeine, tramadol): metoclopramide may inhibit metabolism, raising plasma levels.
• MAO inhibitors: concurrent use can potentiate extrapyramidal side effects.
• Antipsychotics (e.g., haloperidol): additive dopamine antagonism may enhance movement disorders.